Table 5. Univariate and multivariate analysis for PFS and OS in de novo metastatic (n = 45) and HER2-negative (n = 51) patients.
| Univariate analysis | ||||
|---|---|---|---|---|
| Cox regression | PFS | OS | ||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| de novo metastatic | ||||
| Age (<60 vs ≥60) | 1.633 (0.859–3.105) | 0.135 | 1.099 (0.561–2.152) | 0.784 |
| Menopausal status (pre vs post) | 2.420 (1.181–4.957) | 0.016* | 2.402 (1.118–5.161) | 0.025* |
| PS (2-3 vs 0-1) | 2.364 (1.167–4.789) | 0.017* | 3.185 (1.503–6.752) | 0.003 |
| Grade (III vs I/II) | 1.047 (0.509–2.154) | 0.901 | 1.112 (0.524–2.357) | 0.782 |
| ER status (negative vs positive) | 1.229 (0.586–2.580) | 0.585 | 1.388 (0.629–3.062) | 0.417 |
| PR status (negative vs positive) | 1.223 (0.646–2.315) | 0.536 | 1.215 (0.609–2.425) | 0.581 |
| HER2 (positive vs negative) | 1.465 (0.778–2.758) | 0.237 | 1.049 (0.528–2.084) | 0.891 |
| Visceral metastases (yes vs no) | 1.138 (0.549–2.361) | 0.728 | 1.480 (0.704–3.112) | 0.301 |
| Non-visceral metastases (yes vs no) | 1.668 (0.511–5.439) | 0.396 | 1.846 (0.552–6.174) | 0.320 |
| Bone metastases (yes vs no) | 1.235 (0.646–2.361) | 0.524 | 1.889 (0.897–3.979) | 0.094 |
| miR-21 (high vs low) | 2.257 (1.164–4.376) | 0.016* | 1.796 (0.872–3.698) | 0.112 |
| miR-23b (high vs low) | 2.200 (1.150–4.211) | 0.017* | 1.897 (0.954–3.770) | 0.068 |
| miR-190 (high vs low) | 2.023 (1.078–3.794) | 0.028* | 1.080 (0.559–2.083) | 0.819 |
| miR-200b (high vs low) | 1.767 (0.911–3.428) | 0.092 | 2.359 (1.111–5.007) | 0.025 |
| miR-200c (high vs low) | 1.598 (0.85602.982) | 0.141 | 1.022 (0.534–1.954) | 0.948 |
| miR-23b/mir-190 (both high vs others) | 2.857 (1.415–5.767) | 0.003* | 1.477 (0.729–2.992) | 0.279 |
| Multvariate analysis | ||||
| Menopausal status (pre vs post) | 4.125 (1.871–9.091) | <0.001* | 5.658 (2.485–12.879) | <0.001* |
| PS (2-3 vs 0-1) | 3.773 (1.754–8.130) | 0.001* | ||
| miR-23b/miR-190 | 3.670 (1.713–7.867) | 0.001* | ||
| HER2-negative | ||||
| Univariate analysis | ||||
| Age (<63 vs ≥63) | 1.280 (0.700–2.341) | 0.423 | 1.145 (0.625–2.098) | 0.661 |
| Menopausal status (pre vs post) | 1.768 (0.962–3.247) | 0.066 | 1.698 (0.906–3.179) | 0.098 |
| Performanc status (2-3 vs 0-1) | 1.659 (0.763–3.607) | 0.202 | 1.388 (0.635–3.034) | 0.411 |
| Disease status (recurrent vs de novo) | 2.059 (1.132–3.747) | 0.018* | 2.379 (1.296–4.369) | 0.005* |
| Grade (III vs I/II) | 1.077 (0.556–2.087) | 0.826 | 1.252 (0.634–2.473) | 0.517 |
| ER status (negative vs positive) | 1.593 (0.701–3.622) | 0.266 | 1.102 (0.462–2.631) | 0.826 |
| PR status (negative vs positive) | 1.197 (0.614–2.334) | 0.597 | 1.145 (0.572–2.290) | 0.702 |
| Visceral metastases (yes vs no) | 1.002 (0.537–1.868) | 0.996 | 1.060 (0.557–2.018) | 0.859 |
| Non-visceral metastases (yes vs no) | 1.159 (0.512–2.622) | 0.723 | 1.181 (0.520–2.686) | 0.691 |
| Bone metastases (yes vs no) | 1.632 (0.900–2.958) | 0.107 | 1.511 (0.815–2.800) | 0.190 |
| miR-21 (high vs low) | 1.691 (0.927–3.084) | 0.087 | 1.533 (0.807–2.914) | 0.192 |
| miR-23b (high vs low) | 1.715 (0.952–3.088) | 0.072 | 1.336 (0.734–2.432) | 0.343 |
| miR-190 (high vs low) | 1.571 (0.860–2.870) | 0.142 | 1.497 (0.795–2.820) | 0.211 |
| miR-200b (high vs low) | 1.346 (0.739–2.450) | 0.331 | 2.342 (1.214–4.518) | 0.011* |
| miR-200c (high vs low) | 1.169 (0.654–2.091) | 0.598 | 1.333 (0.728–2.440) | 0.352 |
| miR-21/miR-23b (both high vs others) | 1.981 (1.053–3.725) | 0.034* | 1.962 (1.039–3.707) | 0.038* |
| Multvariate analysis | ||||
| Disease status (recurrent vs de novo) | 2.059 (1.132–3.747) | 0.018* | 2.543 (1.372–4.713) | 0.003* |
| miR-200b (high vs low) | 2.531 (1.291–4.962) | 0.007* | ||
PFS, progression free survival; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; *p < 0.05.